Related Experiment Videos

Evaluation of HLA matching for CREG antigens in Europe

T Wujciak1, G Opelz

  • 1Department of Transplantation Immunology, University of Heidelberg, Germany.

Transplantation
|November 7, 1999
PubMed

Insights

Cross-reactive antigen group (CREG) matching for kidney transplants does not improve outcomes. Graft survival depends on HLA-A+B mismatches, not CREG grades, in European cadaver kidney allocation.

Area of Science:

  • Immunogenetics
  • Transplantation immunology
  • Organ allocation

Background:

  • Cross-reactive antigen group (CREG) matching was recently adopted in North America for cadaver kidney allocation.
  • This strategy aims to enhance graft outcomes and increase transplants for patients with rare human leukocyte antigens (HLA).

Purpose of the Study:

  • To evaluate the impact of CREG matching on cadaver kidney transplant outcomes in Western Europe.
  • To compare CREG matching with the conventional HLA-A+B mismatching scheme.

Main Methods:

  • Analysis of 59,516 first cadaver kidney transplants from the Collaborative Transplant Study data.
  • Utilized 10 HLA class I CREGs for comparison against HLA-A+B mismatching.

Main Results:

  • Kidney transplant outcomes are primarily determined by HLA-A+B mismatches, not CREG match grades.
  • Retrospective analysis showed a correlation between CREG and HLA-A+B mismatches.
  • Prospective CREG matching simulations did not demonstrate improved HLA-A+B matching benefits.

Conclusions:

  • Observed positive effects of CREG matching in retrospective analyses are attributed to underlying HLA-A+B matching.
  • CREG-based kidney allocation in Europe would be less effective than the current HLA-A+B+DR allocation system.
Abstract

Related Concept Videos